Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study

被引：0
|
作者：
Monica Tang
Andrea L. Schaffer
Belinda E. Kiely
Benjamin Daniels
Chee K. Lee
Robert J. Simes
Sallie-Anne Pearson
机构：
[1] University of New South Wales,Centre for Big Data Research in Health
[2] University of Sydney,NHMRC Clinical Trials Centre
来源：
Breast Cancer Research and Treatment | 2021年 / 187卷
关键词：
Breast neoplasms; Human epidermal growth factor 2; Trastuzumab; Heart function tests; Observational study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：893 / 902
页数：9
相关论文
共 50 条
  • [21] BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
    Dang, Chau
    Ewer, Michael S.
    Delaloge, Suzette
    Ferrero, Jean-Marc
    Colomer, Ramon
    de la Cruz-Merino, Luis
    Werner, Theresa L.
    Dadswell, Katherine
    Verrill, Mark
    Eiger, Daniel
    Sarkar, Sriparna
    de Haas, Sanne Lysbet
    Restuccia, Eleonora
    Swain, Sandra M.
    CANCERS, 2022, 14 (11)
  • [22] Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
    Harbeck, Nadia
    BREAST, 2022, 62 : S12 - S16
  • [23] Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data
    Gannon, Melissa Ruth
    Dodwell, David
    Miller, Katie
    Medina, Jibby
    Clements, Karen
    Horgan, Kieran
    Park, Min Hae
    Cromwell, David Alan
    EUROPEAN JOURNAL OF CANCER, 2024, 211
  • [24] Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study
    Li, Junjie
    Shao, Zhimin
    Xu, Binghe
    Jiang, Zefei
    Cui, Shude
    Zhang, Jin
    Liao, Ning
    Jiang, Jun
    Wang, Yongsheng
    Ouyang, Quchang
    Ying, Ziwei
    MEDICINE, 2018, 97 (21)
  • [25] Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer The best of ASCO 2019
    Suppan, Christoph
    Balic, Marija
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2019, 12 (04) : 312 - 314
  • [26] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Kurebayashi, Junichi
    Kanomata, Naoki
    Yamashita, Tetsumasa
    Shimo, Toshiro
    Mizutoh, Akiko
    Moriya, Takuya
    Sonoo, Hiroshi
    BREAST CANCER, 2015, 22 (03) : 292 - 299
  • [27] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Junichi Kurebayashi
    Naoki Kanomata
    Tetsumasa Yamashita
    Toshiro Shimo
    Akiko Mizutoh
    Takuya Moriya
    Hiroshi Sonoo
    Breast Cancer, 2015, 22 : 292 - 299
  • [28] Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study
    van Ramshorst, Mette S.
    van Werkhoven, Erik
    Mandjes, Ingrid A. M.
    Schot, Margaret
    Wesseling, Jelle
    Peeters, Marie-Jeanne T. F. D. Vrancken
    Terwogt, Jetske M. Meerum
    Bos, Monique E. M.
    Oosterkamp, Hendrika M.
    Rodenhuis, Sjoerd
    Linn, Sabine C.
    Sonke, Gabe S.
    EUROPEAN JOURNAL OF CANCER, 2017, 74 : 47 - 54
  • [29] HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
    Qin, Tao
    Yuan, Zhongyu
    Peng, Roujun
    Bai, Bing
    Shi, Yanxia
    Teng, Xiaoyu
    Liu, Donggeng
    Wang, Shusen
    ONCOTARGETS AND THERAPY, 2013, 6 : 341 - 347
  • [30] Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy
    Cao, Lu
    Cai, Gang
    Xu, Fei
    Yang, Zhao-Zhi
    Yu, Xiao-Li
    Ma, Jin-Li
    Zhang, Qian
    Wu, Jiong
    Guo, Xiao-Mao
    Chen, Jia-Yi
    MEDICINE, 2016, 95 (32)
12345